Navigation Links
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Date:12/8/2009

PITTSBURGH, Dec. 8 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to Venlafaxine Hydrochloride (HCl) Extended Release (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the generic version of Wyeth's Effexor XR® Capsules, a treatment for major depressive disorder.

Pursuant to the license agreement, Mylan will be granted a non-exclusive license to the relevant patents that would permit Mylan to launch Venlafaxine HCl ER Capsules in the U.S. on or after June 1, 2011, or earlier in limited circumstances. Additional details of the agreement remain confidential.

Venlafaxine HCl ER Capsules had U.S. sales of approximately $2.9 billion for the same strengths for the 12 months ending Sept. 30, according to IMS Health. Currently, Mylan has 129 abbreviated new drug applications (ANDAs) pending U.S. Food and Drug Administration approval representing $85 billion in annual brand sales, according to IMS. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $19.2 billion in annual brand sales, according to IMS.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement and marketing of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
2. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
3. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... S.C., Oct. 21, 2011 Federal, state and local ... growing biomedical research effort with the dedication of a ... for major diseases. The complex, housing 78 ... traditional research approach by combining scientists from different fields ...
... division of Sanofi (EURONEXT: SAN and NYSE: ... study evaluating the immunogenicity and safety of an investigational ... of age and older. Currently licensed influenza vaccines target ... a given year. The data were presented at the ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... Arizona State University is seeking aspiring ... their ideas into solutions, products and services in ... is recruiting participants for AREA48 (Applied Regional Economic ... early-stage entrepreneurs with opportunities to access human and ... ASU is particularly seeking participation from retirees, veterans ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...
(Date:5/21/2013)... 21, 2013 Global Proving Ground (GPG), ... the largest online retailer of health and fitness supplements, ... sports show, Warrior Island. “We cast the show ... & Twitter, with our unique social networking platform,” states ... elite fighters on an island in the Pacific Ocean, ...
Breaking Medicine News(10 mins):Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... and other headaches are more likely to have retinopathy, damage ... severe vision problems or blindness, than those without a ... May 15, 2007, issue of Neurology, the scientific journal of ... researchers reviewed the headache history and eye health of 10,902 ...
... and chronic obstructive pulmonary disease among men has discovered ... progressive inflammatory lung disease (COPD). ,COPD (chronic ... progressive lung disease, such as emphysema and bronchitis. ... 43,000 men, who were already part of the US ...
... of infant mortality, cancer, accidental death, and diabetes than any ... according to a state health official, the Sioux Falls Argus ... Health Department, at the request of the Zaniya Task Force, ... of the state's population and found what he called "very ...
... increase the risk of heart attacks and death in patients who ... caused by plaque build-up on the inside walls of the arteries ... them to harden and narrow. This in addition, can ... , According to a report in the Journal of ...
... new research has found that extremely anxious patients with heart ... death when compared to those with a calmer attitude ... were in greatest danger, while those who initially had high ... risk. ,"Most patients come in very anxious about ...
... lay along the Nile in ancient Egypt and not ... the KNH Centre for Biomedical Egyptology at the ... team discovered the evidence in medical papyri written in ... ,"Classical scholars have always considered the ancient Greeks, ...
Cached Medicine News:Health News:Mid-Life Headaches May Increase Risk of Vision Problems 2Health News:American Indians in South Dakota Have More Health Problems Than Others in State, Nationwide, Health Official Says 2Health News:Dont Worry- Be Good To Your Heart 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 3Health News:Modern Medicine Originated in Egypt, Not Greece 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: